Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

Nature Genetics

Volumn 48, Issue 6, 2016, Pages 607-616

  Campbell, Joshua D ^a,b   Alexandrov, Anton ^c,d   Kim, Jaegil ^a   Wala, Jeremiah ^a,b   Berger, Alice H ^a,b   Pedamallu, Chandra Sekhar ^a,b   Shukla, Sachet A ^a,b   Guo, Guangwu ^a,b   Brooks, Angela N ^a,b   Murray, Bradley A ^a,b   Imielinski, Marcin ^a,b,e   Hu, Xin ^f   Ling, Shiyun ^f   Akbani, Rehan ^f   Rosenberg, Mara ^a   Cibulskis, Carrie ^a   Ramachandran, Aruna ^a,b   Collisson, Eric A ^g   Kwiatkowski, David J ^a,h   Lawrence, Michael S ^a   Weinstein, John N ^f   Verhaak, Roel G W ^f   Wu, Catherine J ^a,b   Hammerman, Peter S ^a,b   Cherniack, Andrew D ^a,b   Getz, Gad ^a,e   Artyomov, Maxim N ^c   Schreiber, Robert ^c   Govindan, Ramaswamy ⁱ   Meyerson, Matthew ^a,b,j   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d ITMO UNIVERSITY   (Russian Federation)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARHGAP35 PROTEIN; CREBBP PROTEIN; DNA METHYLTRANSFERASE 3A; DOT1L PROTEIN; E1A ASSOCIATED P300 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FTSJD1 PROTEIN; K RAS PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; KIT PROTEIN; KRUPPEL LIKE FACTOR 5; MIR205 PROTEIN; MIR21 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PDGFRA PROTEIN; PPP3CA PROTEIN; PROTEIN; PROTEIN KINASE LKB1; RAF PROTEIN; RAF1 PROTEIN; RAS PROTEIN; RASA1 PROTEIN; RBM10 PROTEIN; SCATTER FACTOR RECEPTOR; SOS PROTEIN; TRANSCRIPTION FACTOR SOX2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAV1 PROTEIN; WHSC1L1 PROTEIN; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; BLADDER CANCER; COLORECTAL CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; EXOME; GENE EXPRESSION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HLA SYSTEM; HUMAN; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATION RATE; NOONAN SYNDROME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOKING; SOMATIC MUTATION; SQUAMOUS CELL LUNG CARCINOMA; ADENOCARCINOMA; GENETICS; HUMAN GENOME; LUNG TUMOR; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; DNA COPY NUMBER VARIATIONS; GENOME, HUMAN; HUMANS; LUNG NEOPLASMS; RECURRENCE;

EID: 84966600817     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3564     Document Type: Article

References (68)

1. Stewart, B.W., & Wild, C.P. World Cancer Report 2014 (International Agency for Research on Cancer, 2014
2. Siegel, R.L., Miller, K.D., & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015
3. Samet, J.M., et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin. Cancer Res. 15, 5626-5645 (2009
4. Cardarella, S., & Johnson, B.E. The impact of genomic changes on treatment of lung cancer. Am. J. Respir. Crit. Care Med. 188, 770-775 (2013
5. Vaishnavi, A., et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat. Med. 19, 1469-1472 (2013
6. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014
7. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012
8. Imielinski, M., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012
9. Roberts, S.A., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970-976 (2013
10. Lawrence, M.S., et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014
11. Hoadley, K.A., et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929-944 (2014
12. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576-582 (2015
13. Alexandrov, L.B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
14. Lawrence, M.S., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013
15. Govindan, R., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121-1134 (2012
16. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Campbell, P.J., & Stratton, M.R. Deciphering signatures of mutational processes operative in human cancer. Cell Reports 3, 246-259 (2013
17. Forbes, S.A., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805-D811 (2015
18. Alexandrov, L.B., et al. Clock-like mutational processes in human somatic cells. Nat. Genet. 47, 1402-1407 (2015
19. Quesada, V., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44, 47-52 (2012
20. Bernards, A. GAPs galore A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim. Biophys. Acta 1603, 47-82 (2003
21. Hast, B.E., et al. Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination. Cancer Res. 74, 808-817 (2014
22. Wan, H., et al. Kruppel-like factor 5 is required for perinatal lung morphogenesis and function. Development 135, 2563-2572 (2008
23. Zhao, D., Zheng, H.Q., Zhou, Z., & Chen, C. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res. 70, 4728-4738 (2010
24. Zhang, X., et al. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat. Genet. 48, 176-182 (2016
25. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014
26. Zack, T.I., et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134-1140 (2013
27. Akagi, I., et al. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. Cancer Res. 73, 3821-3832 (2013
28. Saito, M., et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin. Cancer Res. 17, 1875-1882 (2011
29. Lebanony, D., et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J. Clin. Oncol. 27, 2030-2037 (2009
30. Oxnard, G.R., Binder, A., & Jänne, P.A. New targetable oncogenes in non-small-cell lung cancer. J. Clin. Oncol. 31, 1097-1104 (2013
31. Stransky, N., Cerami, E., Schalm, S., Kim, J.L., & Lengauer, C. The landscape of kinase fusions in cancer. Nat. Commun. 5, 4846 (2014
32. Gallant, J.N., et al. EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov. 5, 1155-1163 (2015
33. Ye, K., et al. Systematic discovery of complex insertions and deletions in human cancers. Nat. Med. 22, 97-104 (2016
34. Pao, W., & Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175-180 (2011
35. Pao, W., & Hutchinson, K.E. Chipping away at the lung cancer genome. Nat. Med. 18, 349-351 (2012
36. Stephen, A.G., Esposito, D., Bagni, R.K., & McCormick, F. Dragging Ras back in the ring. Cancer Cell 25, 272-281 (2014
37. Rajalingam, K., Schreck, R., Rapp, U.R., & Albert, S. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 1773, 1177-1195 (2007
38. Lepri, F., et al. SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum. Mutat. 32, 760-772 (2011
39. Swanson, K.D., et al. SOS1 mutations are rare in human malignancies: implications for Noonan syndrome patients. Genes Chromosom. Cancer 47, 253-259 (2008
40. Yu, B., et al. Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell 140, 246-256 (2010
41. Shan, L., et al. Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Lung Cancer 89, 337-342 (2015
42. Sholl, L.M., et al. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res. 69, 8341-8348 (2009
43. Liu, Y., et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 3, 870-879 (2013
44. Kim, H.S., et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155, 552-566 (2013
45. Brahmer, J., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135 (2015
46. Rizvi, N.A., et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015
47. Shukla, S.A., et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152-1158 (2015
48. Gubin, M.M., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014
49. Zhang, J., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259 (2014
50. De Bruin, E.C., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014
51. Peifer, M., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104-1110 (2012
52. DePristo, M.A., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011
53. Cibulskis, K., et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601-2602 (2011
54. Carter, S.L., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012
55. Cibulskis, K., et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013
56. Olshen, A.B., Venkatraman, E.S., Lucito, R., & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004
57. Mermel, C.H., et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011
58. Wang, K., et al. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 38, e178 (2010
59. Li, B., & Dewey, C.N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011
60. Brooks, A.N., et al. Conservation of an RNA regulatory map between Drosophila and mammals. Genome Res. 21, 193-202 (2011
61. Yoshihara, K., et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene 34, 4845-4854 (2015
62. Torres-García, W., et al. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics 30, 2224-2226 (2014
63. Alberts, B. Molecular Biology of the Cell (Garland Science, 2002
64. Nielsen, M., Lundegaard, C., Lund, O., & Keşmir, C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57, 33-41 (2005
65. Nielsen, M., et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12, 1007-1017 (2003
66. Hoof, I., et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 61, 1-13 (2009
67. Peters, B., & Sette, A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 6, 132 (2005
68. Kim, Y., Sidney, J., Pinilla, C., Sette, A., & Peters, B. Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior. BMC Bioinformatics 10, 394 (2009